SCHEMBL3370992

SCHEMBL3370992

CCOC(=O)/C(=C/c1ccc(OCc2ccccc2)c(F)c1)OCC

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H4 Q96RI1 1/20 0.53
LMNA P02545 2/20 0.48
KDM4E B2RXH2 2/20 0.48
MRGPRX4 Q96LA9 2/20 0.46
MAPT P10636 1/20 0.45
ALDH1A1 P00352 4/20 0.45
PTPN2 P17706 2/20 0.43
PTPN1 P18031 2/20 0.43
ACP1 P24666 2/20 0.43
S1PR5 Q9H228 1/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
ERN1 O75460 1/20 0.43
POLB P06746 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
APP P05067 1/20 0.42
FFAR1 O14842 2/20 0.41
PPARG P37231 1/20 0.41
PPARD Q03181 1/20 0.41
PPARA Q07869 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3370127 0.88 NR1H4 (0.55) NR1H4LMNAKDM4EMRGPRX4MAPT
SCHEMBL5992736 0.86 LMNA (0.60) NR1H4LMNAKDM4EMAPTALDH1A1
SCHEMBL3370598 0.86 LMNA (0.60) NR1H4LMNAKDM4EMAPTALDH1A1
SCHEMBL2436006 0.86 NR1H4 (0.52) NR1H4LMNAKDM4EMAPTALDH1A1
SCHEMBL2436007 0.86 NR1H4 (0.52) NR1H4LMNAKDM4EMAPTALDH1A1
SCHEMBL979378 0.85 NR1H4 (0.52) NR1H4LMNAKDM4EMAPTALDH1A1
SCHEMBL979377 0.85 NR1H4 (0.52) NR1H4LMNAKDM4EMAPTALDH1A1
SCHEMBL5578964 0.82 NR1H4 (0.53) NR1H4LMNAKDM4EMRGPRX4MAPT
SCHEMBL5578962 0.82 NR1H4 (0.53) NR1H4LMNAKDM4EMRGPRX4MAPT
SCHEMBL3374613 0.81 KDM4E (0.47) NR1H4LMNAKDM4EMRGPRX4MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1537091-B1 NOVEL 2-ARYLTHIAZOLE COMPOUNDS AS PPARALPHA AND PPARGAMMA AGONISTS HOFFMANN LA ROCHE (CH) 2010-10-06 EP disclosed
EP-1537091-A1 NOVEL 2-ARYLTHIAZOLE COMPOUNDS AS PPARALPHA AND PPARGAMMA AGONISTS F.HOFFMANN-LA ROCHE AG (CH) 2005-06-08 EP disclosed
US-6809110-B2 NONINSULIN DEPENDENT DIABETES; SUCH AS 2-ETHOXY-3-(4-(2-(5-METHYL-2-PHENYL-THIAZOL-4-YL)-ETHOXY)-BENZO(B)THIOPHEN-7-YL)-PROPIONIC ACID HOFFMANN-LA ROCHE INC. 2004-10-26 US disclosed
US-20040110807-A1 Thiazole derivatives HOFFMANN-LA ROCHE INC. 2004-06-10 US disclosed
WO-2004020420-A1 NOVEL 2-ARYLTHIAZOLE COMPOUNDS AS PPARALPHA AND PPARGAMA AGONISTS F.HOFFMANN-LA ROCHE AG (CH) 2004-03-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110807-A1 Thiazole derivatives SLC5A1, GPR119, INSR NR1H4 512/4885LMNA 3464/4885KDM4E 3260/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.